EDA2R Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the HAP1 cell line, engineered to disrupt the expression of the EDA2R gene. This loss-of-function model is generated via Cas9-mediated gene targeting, resulting in a heterogeneous knockout pool suitable for population-level functional assays without clonal selection. The product enables robust interrogation of EDA2R-dependent signaling while minimizing clonal artifacts, making it ideal for screening applications where polyclonal representation enhances biological relevance.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia (CML) cell line. Its haploid karyotype, except for a disomic chromosome 8 fragment, permits straightforward genetic manipulation and facilitates the isolation of complete loss-of-function mutations. Widely adopted as a screening platform for functional genomics, HAP1 cells maintain key leukemic signaling networks, providing a relevant context for studying cancer-associated pathways and apoptosis regulation.
EDA2R encodes a death domain-containing member of the tumor necrosis factor receptor superfamily that specifically binds the EDA-A2 ligand. Ligand engagement triggers receptor trimerization and recruitment of adaptor proteins including TRAF6, TRAF2, and FADD, leading to assembly of signaling complexes that activate the IKK complex. This results in NF-??B translocation to the nucleus and concurrent phosphorylation of JNK, which together promote transcription of target genes. Additionally, EDA2R signaling can induce apoptosis through recruitment and activation of caspase-8, linking the receptor to the extrinsic apoptotic pathway. Transcriptional regulation of EDA2R is influenced by TP53, positioning it at a key node in p53-mediated stress responses.
Disruption of EDA2R in the HAP1 background creates a powerful tool for dissecting its role in CML cell biology and p53-dependent apoptosis. Because HAP1 cells retain features of leukemic progenitors, this knockout model allows researchers to assess EDA2R contributions to cancer cell survival, NF-??B-driven cytokine production, and JNK-mediated stress signals. Moreover, the near-haploid genome simplifies the mapping of genetic interactions involving EDA2R and its signaling partners, facilitating synthetic lethality screens and investigation of resistance mechanisms in leukemia.
This knockout polyclonal product is ideally suited for a variety of experimental approaches, including apoptosis assays using caspase-3 or caspase-8 activity measurements, NF-??B reporter assays to monitor pathway activation, western blotting for phospho-JNK or I??B?? degradation, and RT-qPCR to quantify downstream target genes. Flow cytometry can be used to assess surface markers or apoptotic populations. Researchers studying hypohidrotic ectodermal dysplasia, NF-??B pathobiology, or cancer cell signaling will find these cells valuable for delineating EDA2R-dependent processes. For further details or technical support, please contact Ascent Research.
